NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that its subsidiary, SIGA Pharmaceuticals (Europe) Limited, has qualified as a ‘small and medium-sized enterprise’ (SME) with respect to its application for approval of ST-246 in Europe. ST-246 is a smallpox antiviral and SIGA’s lead product candidate. SIGA has also initiated the process for obtaining Marketing Authorization with ST-246 with the EMEA, which is the European equivalent of the United States Food and Drug Administration.
